FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI

 

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply